脊柱与非脊柱骨转移立体定向体部放疗后的疗效评估:一项单中心研究结果
该单中心回顾性研究分析了2008年12月至2018年10月间接受骨立体定向体部放疗(SBRT)的74例患者中的35例合格患者(43处骨转移灶),采用MD安德森癌症中心标准评估影像学反应。中位随访1.8年,局部控制率达80%,有症状可随访患者中44.4%报告疼痛减轻。作者认为需以前瞻性标准化方式比较当前影像与功能MRI、PET/CT等先进影像技术以更准确评估疗效。
要点
- 骨SBRT后80%患者达到局部控制,完全缓解0%、部分缓解11.4%、稳定68.6%、进展20.0%。
- 有症状且可随访患者中44.4%报告疼痛减轻。
- 作者认为需以前瞻性标准化方式比较当前影像与先进影像技术以更准确评估疗效。
核心结论
- 80%的患者在骨转移SBRT后显示局部控制,疼痛反应良好。
- 作者认为需以前瞻性标准化方式比较当前影像模式与功能MRI、PET/CT等先进影像技术,以更准确评估疗效。
研究设计与样本
- 单中心回顾性分析,纳入2008年12月至2018年10月在本机构接受SBRT的寡转移/进展性骨病变患者,排除野内再照射。
- 从PACS获取SBRT计划与随访影像数据,由两名对治疗时间不知情的独立放射科医生评估。
- 影像学反应按德克萨斯大学MD安德森癌症中心标准分类;疼痛反应和神经功能缺损在SBRT前及至少6个月后采集。
主要发现
- 74例回顾患者中35例合格,共43处骨转移灶,51.2%(n=22)位于脊柱。
- SBRT时中位年龄66岁(范围38-84),男性77.1%(n=27);组织学主要为前列腺癌51.4%(n=18)和乳腺癌14.3%(n=5)。
- 中位总放疗剂量24 Gy(范围24-42),分3次(范围2-7次),处方至70-90%等剂量线。
- 幸存者中位随访1.8年(范围<1-8.2年);完全缓解0%、部分缓解11.4%(n=4)、稳定68.6%(n=24)、进展20.0%(n=7)。
- 随访期间20例(57.1%)死亡,均死于疾病进展,其中70%(n=14)死亡时局部稳定;有症状且可随访患者中44.4%报告疼痛减轻。
局限性
- 原文为回顾性研究。
- 原文为单中心机构研究。
- 作者结论提出需以前瞻性标准化方式比较当前影像与先进影像技术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of stereotactic body radiation therapy (SBRT) for tumor and pain control in patients with bone metastases is increasing. We report response assessment after bone SBRT using radiological changes through time and clinical examination of patients. METHODS: We analyzed retrospectively oligo-metastatic/progressive patients with bony lesions treated with SBRT between 12/2008 and 10/2018, without in-field re-irradiation, in our institution. Radiological data were obtained from imaging modalities used for SBRT planning and follow-up purposes in picture archiving and communication system and assessed by two independent radiologists blind to the time of treatment. Several radiological changes were described. Radiographic response assessment was classified according to University of Texas MD Anderson Cancer Center criteria. Pain response and the neurological deficit were captured before and at least 6 months after SBRT. RESULTS: A total of 35 of the 74 reviewed patients were eligible, presenting 43 bone metastases, with 51.2% (n = 22) located in the vertebral column. Median age at the time of SBRT was 66 years (range 38-84) and 77.1% (n = 27) were male. Histology was mainly prostate (51.4%, n = 18) and breast cancer (14.3%, n = 5). Median total radiation dose delivered was 24 Gy (range 24-42), in three fractions (range 2-7), prescribed to 70-90% isodose-line. After a median follow-up of 1.8 years (range < 1-8.2) for survivors, complete or partial response, stable, and progressive disease occurred in 0%, 11.4% (n = 4), 68.6% (n = 24), and 20.0% (n = 7) of the patients, respectively. Twenty patients (57.1%) died during the follow-up time, all from disease progression, yet 70% (n = 14) from this population with local stable disease after SBRT. From patients who were symptomatic and available for follow-up, almost half (44.4%) reported pain reduction after SBRT. CONCLUSIONS: Eighty percent of the patients showed local control after SBRT for bone metastases. Pain response was favorable. For more accurate response assessment, comparing current imaging modalities with advanced imaging techniques such as functional MRI and PET/CT, in a prospective and standardized way is warranted. Trial registration Retrospectively registered.
引用
- Correia D, Moullet B, Cullmann J, et al. Response assessment after stereotactic body radiation therapy for spine and non-spine bone metastases: results from a single institutional study. Radiat Oncol. 2022. PMID: 35189919. doi:10.1186/s13014-022-02004-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。